Gritstone Bio Cash on Hand 2017-2024 | GRTSQ
Gritstone Bio cash on hand from 2017 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Gritstone Bio Annual Cash on Hand
(Millions of US $) |
| 2023 |
$82 |
| 2022 |
$176 |
| 2021 |
$213 |
| 2020 |
$171 |
| 2019 |
$128 |
| 2018 |
$153 |
| 2017 |
$86 |
| 2016 |
$38 |
Gritstone Bio Quarterly Cash on Hand
(Millions of US $) |
| 2024-06-30 |
$57 |
| 2024-03-31 |
$48 |
| 2023-12-31 |
$82 |
| 2023-09-30 |
$85 |
| 2023-06-30 |
$117 |
| 2023-03-31 |
$148 |
| 2022-12-31 |
$176 |
| 2022-09-30 |
$147 |
| 2022-06-30 |
$154 |
| 2022-03-31 |
$182 |
| 2021-12-31 |
$213 |
| 2021-09-30 |
$211 |
| 2021-06-30 |
$171 |
| 2021-03-31 |
$198 |
| 2020-12-31 |
$171 |
| 2020-09-30 |
$71 |
| 2020-06-30 |
$92 |
| 2020-03-31 |
$109 |
| 2019-12-31 |
$128 |
| 2019-09-30 |
$149 |
| 2019-06-30 |
$181 |
| 2019-03-31 |
$132 |
| 2018-12-31 |
$153 |
| 2018-09-30 |
$77 |
| 2018-06-30 |
|
| 2018-03-31 |
|
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2016-12-31 |
$38 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
